Who
Benjamin Looker
Chief Legal Officer
Company insider
Files Form 4 as: Chief Legal Officer, Esperion Therapeutics; General Counsel, Trillium Therapeutics.
In numbers
- Trades disclosed
- 36
- Buys
- 0
- Sells
- 10
- Bought
- $0
- Sold
- $215K
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 3 May 2021
- Last trade
- 13 Jul 2026
- Last filed
- 13 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 13 Jul 2026filed 13 Jul 2026 | Esperion TherapeuticsBiotechnology | SEC FORM 4 Code D | —667,524 | filing |
| 13 Jul 2026filed 13 Jul 2026 | Esperion Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —150,000 | filing |
| 13 Jul 2026filed 13 Jul 2026 | Esperion Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —201,000 | filing |
| 13 Jul 2026filed 13 Jul 2026 | Esperion Therapeuticsoption or derivative | SEC FORM 4 Code D | —150,000 | filing |
| 13 Jul 2026filed 13 Jul 2026 | Esperion Therapeuticsoption or derivative | SEC FORM 4 Code D | —201,000 | filing |
| 13 Jul 2026filed 13 Jul 2026 | Esperion Therapeuticsoption or derivative | SEC FORM 4 Code D | —269,230 | filing |
| 13 Jul 2026filed 13 Jul 2026 | Esperion Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —269,230 | filing |
| 13 Jul 2026filed 13 Jul 2026 | Esperion Therapeutics | SEC FORM 4 Code D | —667,524 | filing |
| 17 Jun 2026filed 18 Jun 2026 | Esperion TherapeuticsBiotechnology | SEC FORM 4 Sold | $37K11,824 at $3.16 | filing |
| 17 Jun 2026filed 18 Jun 2026 | Esperion Therapeutics | SEC FORM 4 Sold | $37K11,824 at $3.16 | filing |
| 17 Mar 2026filed 18 Mar 2026 | Esperion TherapeuticsBiotechnology | SEC FORM 4 Sold | $15K5,708 at $2.70 | filing |
| 17 Mar 2026filed 18 Mar 2026 | Esperion Therapeutics | SEC FORM 4 Sold | $15K5,708 at $2.70 | filing |
| 13 Mar 2026filed 16 Mar 2026 | Esperion TherapeuticsBiotechnology | SEC FORM 4 Code A | —300,840 at $0.00 | filing |
| 13 Mar 2026filed 16 Mar 2026 | Esperion Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —269,230 at $0.00 | filing |
| 13 Mar 2026filed 16 Mar 2026 | Esperion Therapeuticsoption or derivative | SEC FORM 4 Code A | —269,230 at $0.00 | filing |
| 13 Mar 2026filed 16 Mar 2026 | Esperion Therapeutics | SEC FORM 4 Code A | —300,840 at $0.00 | filing |
| 20 Jan 2026filed 21 Jan 2026 | Esperion TherapeuticsBiotechnology | SEC FORM 4 Sold | $4,8681,689 at $2.88 | filing |
| 20 Jan 2026filed 21 Jan 2026 | Esperion Therapeutics | SEC FORM 4 Sold | $4,8641,689 at $2.88 | filing |
| 17 Dec 2025filed 18 Dec 2025 | Esperion Therapeutics | SEC FORM 4 Sold | $24K6,517 at $3.67 | filing |
| 17 Oct 2025filed 20 Oct 2025 | Esperion Therapeutics | SEC FORM 4 Sold | $3,2701,248 at $2.62 | filing |
News
No headline names them, or the companies they trade most, lately.